Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
- Conditions
- Overt Hepatic Encephalopathy
- Interventions
- Drug: Human albumin infusion at a modified dosageDrug: Human albumin infusion at a routine dosageDrug: Branched-Chain Amino Acids
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Target Recruit Count
- 174
- Registration Number
- NCT06483737
- Locations
- 🇨🇳
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang, Liaoning, China
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 16
- Registration Number
- NCT06312683
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 80
- Registration Number
- NCT06234046
- Locations
- 🇪🇬
Mostafa Elfors, Cairo, Egypt
The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin
- Conditions
- Small Intestinal Bacterial OvergrowthIrritable Bowel SyndromeSIBO
- Interventions
- Dietary Supplement: Probiotic
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Pomeranian Medical University Szczecin
- Target Recruit Count
- 125
- Registration Number
- NCT06223685
- Locations
- 🇵🇱
Sonomed CENTRUM MEDYCZNE, Szczecin, Zachodniopomorskie, Poland
Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 280
- Registration Number
- NCT06199843
- Locations
- 🇮🇳
Dr Jaya Benjamin, New Delhi, Delhi, India
Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia
- Conditions
- Acute Leukemia
- Interventions
- Procedure: Allogeneic stem cell transplant
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 166
- Registration Number
- NCT06058572
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Bahria University
- Target Recruit Count
- 162
- Registration Number
- NCT05867550
- Locations
- 🇵🇰
Bahria University Health Sciences Campus, Karachi, Sindh, Pakistan
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
- Conditions
- Decompensated Cirrhosis
- Interventions
- Drug: Conventional dose of Rifaximin
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Xin Zeng
- Target Recruit Count
- 150
- Registration Number
- NCT05863364
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
The Efficacy and Safety of Rifaximin Treatment
- Conditions
- Hepatitis BEffect of DrugLiver Failure, Acute on ChronicHBVHepatic EncephalopathyRifaximin
- Interventions
- Other: Standard Treatment without Rifaximin
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 124
- Registration Number
- NCT05786859
- Locations
- 🇨🇳
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis
- Conditions
- Hepatic Encephalopathy
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 102
- Registration Number
- NCT05754996
- Locations
- 🇪🇬
National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.